Mechanism: Immune Signalling
Thymosin Alpha-1 vs BPC-157: Mechanism Comparison
Both peptides have immunomodulatory properties but they act on different arms of the immune system. Thymosin Alpha-1 directly modulates T cell function. BPC-157 supports gut barrier integrity, indirectly shaping immune tone.
Side-by-side comparison
| Attribute | Thymosin Alpha-1 | BPC-157 |
|---|---|---|
| Primary mechanism | T cell modulation, dendritic cell maturation | Gut barrier repair, angiogenic and anti-inflammatory |
| Regulatory status | Approved in many countries | Unapproved, research use |
| Strongest evidence | Hepatitis B, sepsis, cancer adjunct trials | Rodent gut and musculoskeletal injury |
| Typical research dose | 1.6 mg twice weekly subcutaneous | 250 to 500 mcg daily subcutaneous or oral |
Key differences
- ·Thymosin Alpha-1 is approved in over 35 countries for hepatitis B and immune modulation
- ·BPC-157 immune effects are downstream of GI barrier repair
- ·Thymosin Alpha-1 directly upregulates Th1 cytokines and dendritic cell maturation
- ·BPC-157 reduces inflammatory markers in gut injury models
Research summary
Garaci et al. (2007) reviewed Thymosin Alpha-1 immune effects across viral and oncology indications. Sikiric et al. (2018) summarised BPC-157 gut and systemic anti-inflammatory data. The peptides complement rather than substitute.